Hepatitis E Vaccine Production Base
The production base covers an area of approximately 13,000 m2, with a total construction area of about 12,700 m2 and an investment of hundreds of millions of RMB. The production base is equipped with a hepatitis E vaccine production workshop and supporting facilities, including purified water and Water for Injection (WFI) system, wastewater treatment facilities, and SPF-grade animal rooms.
HPV Vaccine Manufacturing Base
The bivalent HPV vaccine facility, with an investment of RMB 500 million, began operations in 2017. The plant meets GMP standards and operates under strict quality management systems in compliance with WHO PQ requirements.
The 9-valent HPV vaccine production facility, with an investment of RMB 1 billion, has production lines designed to meet regulatory standards from the U.S. FDA, EMA, and WHO-PQ. The facility utilizes advanced equipment including PSA tubular centrifuges, automated fermentation systems, and chromatography systems.